124 related articles for article (PubMed ID: 18664606)
1. Postdischarge oral versus injectable anticoagulation following major orthopedic surgery.
Shorr AF; Nutescu EA; Farrelly E; Horblyuk R; Happe LE; Franklin M
Ann Pharmacother; 2008 Sep; 42(9):1222-8. PubMed ID: 18664606
[TBL] [Abstract][Full Text] [Related]
2. Burden of deep vein thrombosis in the outpatient setting following major orthopedic surgery.
Nutescu EA; Shorr AF; Farrelly E; Horblyuk R; Happe LE; Franklin M
Ann Pharmacother; 2008 Sep; 42(9):1216-21. PubMed ID: 18611992
[TBL] [Abstract][Full Text] [Related]
3. Decreased venous thromboembolism with injectable vs oral anticoagulation after discharge for major orthopedic surgery.
Kwong LM; Happe LE; Horblyuk R; Farrelly E
J Arthroplasty; 2008 Sep; 23(6 Suppl 1):25-30. PubMed ID: 18722300
[TBL] [Abstract][Full Text] [Related]
4. Need to improve thromboprophylaxis across the continuum of care for surgical patients.
Amin AN; Lin J; Ryan A
Adv Ther; 2010 Feb; 27(2):81-93. PubMed ID: 20390389
[TBL] [Abstract][Full Text] [Related]
5. Venous thromboembolism after orthopedic surgery: implications of the choice for prophylaxis.
Shorr AF; Kwong LM; Sarnes M; Happe L; Farrelly E; Mody-Patel N
Thromb Res; 2007; 121(1):17-24. PubMed ID: 17449088
[TBL] [Abstract][Full Text] [Related]
6. Outpatient treatment of venous thromboembolism with low-molecular-weight heparin: an economic evaluation.
Huse DM; Cummins G; Taylor DC; Russell MW
Am J Manag Care; 2002 Jan; 8(1 Suppl):S10-6. PubMed ID: 11822346
[TBL] [Abstract][Full Text] [Related]
7. Clinical and economic outcomes in patients at risk of venous thromboembolism receiving appropriate enoxaparin or unfractionated heparin prophylaxis.
Amin AN; Lin J; Lenhart G; Schulman KL
Thromb Haemost; 2009 Aug; 102(2):321-6. PubMed ID: 19652883
[TBL] [Abstract][Full Text] [Related]
8. Thromboembolic consequences of subtherapeutic anticoagulation in patients stabilized on warfarin therapy: the low INR study.
Clark NP; Witt DM; Delate T; Trapp M; Garcia D; Ageno W; Hylek EM; Crowther MA;
Pharmacotherapy; 2008 Aug; 28(8):960-7. PubMed ID: 18657012
[TBL] [Abstract][Full Text] [Related]
9. Use of emerging oral anticoagulants in clinical practice: translating results from clinical trials to orthopedic and general surgical patient populations.
Merli G; Spyropoulos AC; Caprini JA
Ann Surg; 2009 Aug; 250(2):219-28. PubMed ID: 19638915
[TBL] [Abstract][Full Text] [Related]
10. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
Huo MH; Muntz J
Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
[TBL] [Abstract][Full Text] [Related]
11. Dalteparin versus enoxaparin for venous thromboembolism prophylaxis in acute spinal cord injury and major orthopedic trauma patients: 'DETECT' trial.
Slavik RS; Chan E; Gorman SK; de Lemos J; Chittock D; Simons RK; Wing PC; Ho SG
J Trauma; 2007 May; 62(5):1075-81; discussion 1081. PubMed ID: 17495705
[TBL] [Abstract][Full Text] [Related]
12. Risk of thromboembolism with short-term interruption of warfarin therapy.
Garcia DA; Regan S; Henault LE; Upadhyay A; Baker J; Othman M; Hylek EM
Arch Intern Med; 2008 Jan; 168(1):63-9. PubMed ID: 18195197
[TBL] [Abstract][Full Text] [Related]
13. Comparison of cost, effectiveness, and safety of injectable anticoagulants used for thromboprophylaxis after orthopedic surgery.
Shorr AF; Sarnes MW; Peeples PJ; Stanford RH; Happe LE; Farrelly E
Am J Health Syst Pharm; 2007 Nov; 64(22):2349-55. PubMed ID: 17989444
[TBL] [Abstract][Full Text] [Related]
14. Cost and occurrence of thrombocytopenia in patients receiving venous thromboembolism prophylaxis following major orthopaedic surgeries.
Happe LE; Farrelly EM; Stanford RH; Sarnes MW
J Thromb Thrombolysis; 2008 Oct; 26(2):125-31. PubMed ID: 18034323
[TBL] [Abstract][Full Text] [Related]
15. Comparison of the two-year outcomes and costs of prophylaxis in medical patients at risk of venous thromboembolism.
Deitelzweig SB; Becker R; Lin J; Benner J
Thromb Haemost; 2008 Nov; 100(5):810-20. PubMed ID: 18989525
[TBL] [Abstract][Full Text] [Related]
16. Impact of an inpatient anticoagulation management service on clinical outcomes.
Biscup-Horn PJ; Streiff MB; Ulbrich TR; Nesbit TW; Shermock KM
Ann Pharmacother; 2008 Jun; 42(6):777-82. PubMed ID: 18460587
[TBL] [Abstract][Full Text] [Related]
17. Low-molecular-weight heparin, bemiparin, in the outpatient treatment and secondary prophylaxis of venous thromboembolism in standard clinical practice: the ESFERA Study.
Santamaría A; Juárez S; Reche A; Gómez-Outes A; Martínez-González J; Fontcuberta J;
Int J Clin Pract; 2006 May; 60(5):518-25. PubMed ID: 16700847
[TBL] [Abstract][Full Text] [Related]
18. Pharmacotherapy adherence and costs versus nonpharmacologic management in overactive bladder.
Pelletier EM; Vats V; Clemens JQ
Am J Manag Care; 2009 Mar; 15(4 Suppl):S108-14. PubMed ID: 19355799
[TBL] [Abstract][Full Text] [Related]
19. Comparison of safety of subcutaneous enoxaparin as outpatient anticoagulation bridging therapy in patients with a mechanical heart valve versus patients with nonvalvular atrial fibrillation.
Bui HT; Krisnaswami A; Le CU; Chan J; Shenoy BN
Am J Cardiol; 2009 Nov; 104(10):1429-33. PubMed ID: 19892063
[TBL] [Abstract][Full Text] [Related]
20. The economic effect of oral linezolid versus intravenous vancomycin in the outpatient setting: the payer perspective.
McKinnon PS; Carter CT; Girase PG; Liu LZ; Carmeli Y
Manag Care Interface; 2007 Jan; 20(1):23-34. PubMed ID: 17310650
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
